vs
Side-by-side financial comparison of LiveRamp Holdings, Inc. (RAMP) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $212.2M, roughly 1.5× LiveRamp Holdings, Inc.). LiveRamp Holdings, Inc. runs the higher net margin — 18.8% vs 16.4%, a 2.4% gap on every dollar of revenue. On growth, LiveRamp Holdings, Inc. posted the faster year-over-year revenue change (8.6% vs -1.5%). Over the past eight quarters, LiveRamp Holdings, Inc.'s revenue compounded faster (11.1% CAGR vs 1.3%).
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
RAMP vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $212.2M | $311.4M |
| Net Profit | $39.9M | $51.0M |
| Gross Margin | 71.9% | 66.9% |
| Operating Margin | 18.6% | 24.2% |
| Net Margin | 18.8% | 16.4% |
| Revenue YoY | 8.6% | -1.5% |
| Net Profit YoY | 255.7% | 126.0% |
| EPS (diluted) | $0.62 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $212.2M | $295.9M | ||
| Q3 25 | $199.8M | — | ||
| Q2 25 | $194.8M | $317.0M | ||
| Q1 25 | $188.7M | $316.2M | ||
| Q4 24 | $195.4M | $297.0M | ||
| Q3 24 | $185.5M | $289.5M | ||
| Q2 24 | $176.0M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $39.9M | $38.0M | ||
| Q3 25 | $27.4M | — | ||
| Q2 25 | $7.7M | $-17.7M | ||
| Q1 25 | $-6.3M | $22.6M | ||
| Q4 24 | $11.2M | $34.9M | ||
| Q3 24 | $1.7M | $33.6M | ||
| Q2 24 | $-7.5M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 71.9% | 64.6% | ||
| Q3 25 | 70.2% | — | ||
| Q2 25 | 70.1% | 62.7% | ||
| Q1 25 | 69.3% | 67.9% | ||
| Q4 24 | 71.9% | 65.3% | ||
| Q3 24 | 72.4% | 63.2% | ||
| Q2 24 | 70.6% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 18.6% | 18.4% | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 3.7% | -7.5% | ||
| Q1 25 | -6.1% | 12.2% | ||
| Q4 24 | 7.5% | 16.0% | ||
| Q3 24 | 4.0% | 13.8% | ||
| Q2 24 | -3.0% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | 18.8% | 12.8% | ||
| Q3 25 | 13.7% | — | ||
| Q2 25 | 4.0% | -5.6% | ||
| Q1 25 | -3.3% | 7.1% | ||
| Q4 24 | 5.7% | 11.7% | ||
| Q3 24 | 0.9% | 11.6% | ||
| Q2 24 | -4.3% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.62 | $0.24 | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.12 | $-0.11 | ||
| Q1 25 | $-0.10 | $0.14 | ||
| Q4 24 | $0.17 | $0.22 | ||
| Q3 24 | $0.03 | $0.21 | ||
| Q2 24 | $-0.11 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $403.4M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $962.3M | $2.1B |
| Total Assets | $1.3B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $403.4M | $172.9M | ||
| Q3 25 | $376.9M | — | ||
| Q2 25 | $371.1M | $162.2M | ||
| Q1 25 | $420.8M | $140.7M | ||
| Q4 24 | $384.3M | $177.5M | ||
| Q3 24 | $348.4M | $187.5M | ||
| Q2 24 | $342.7M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $962.3M | $2.0B | ||
| Q3 25 | $943.8M | — | ||
| Q2 25 | $947.8M | $1.9B | ||
| Q1 25 | $948.9M | $2.0B | ||
| Q4 24 | $957.7M | $2.1B | ||
| Q3 24 | $932.1M | $2.1B | ||
| Q2 24 | $951.9M | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.3B | $2.5B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $1.2B | $2.7B | ||
| Q2 24 | $1.2B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RAMP
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
